Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Frontier Biotech of Nanjing Announces $43 Million Funding

publication date: Jan 4, 2017
Nanjing Frontier Biotech has raised $43 million in a Series C funding round led by Huaxin Century Investment Group, a Beijing RMB fund. Frontier recently announced that its NDA for Albuvirtide, a novel treatment for AIDS, was accepted by the CFDA for accelerated approval. Albuvirtide is a long-acting HIV fusion inhibitor that is administered via an IV on a once-weekly basis. If approved, Albuvirtide will be China's first domestically developed novel AIDS treatment. The company said it will use the capital to market Albuvirtide and continue research on other products. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital